highly significantP = 0.001
After adjusting for baseline levels and GP IIb/IIIa inhibitor use using GLM, the between‐group differences at 6 months remained highly significant (CRP: adjusted P = 0.001; IL‐6: adjusted P < 0.001; PCT: adjusted P = 0.003).